Search
Returning search results with filters:
Remove filter for
Audience: Industry
Remove filter for
Recall class: Type I
Clear all
Type
Audience
Category
Issue
Last updated
Recall class
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 15 of 15 items.
Taro Pharmaceuticals Inc. is recalling all lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because they may contain particulate matter.
Zoledronic acid is a prescription drug used to treat and prevent osteoporosis and to treat Paget's…
RecallHealth product recall | 2022-08-10
Jamp Pharma Corporation is recalling one lot (MHC1403A) of Jamp-Atorvastatin 40 mg tablets due to possible contamination with latex pieces during manufacturing. A piece of latex was found in one tablet from the affected lot.…
RecallHealth product recall | 2022-08-08
Solution bags may be leaking in affected lot.
RecallHealth product recall | 2022-08-04
Affected lot exceeds concentration limit for N-nitrosodimethylamine (NDMA).
RecallHealth product recall | 2022-07-28
Affected lot(s) may contain the presence of particulate matter.
RecallHealth product recall | 2022-07-15
The sterility is out of specification in the affected lot (Periodic Media Fill Validation failure).
RecallHealth product recall | 2022-06-30
The products may contain undeclared ingredients which are listed on the Prescription Drug List.
RecallHealth product recall | 2022-06-21
All lots contain an undeclared ingredient (sildenafil) that is listed on the prescription drug list.
RecallHealth product recall | 2022-06-01
Our contract manufacturer sent us a FSCA identifying deviations in their sterilisation process and therefore we can not guarantee the sterility of the products.
Recall start date: May 18, 2022
RecallHealth product recall | 2022-05-30
The assay is out of specification in the affected lot(s).
RecallHealth product recall | 2022-05-13
Presence of N-Nitroso-quinapril above the acceptable concentration limit in affected lots.
RecallHealth product recall | 2022-04-20
Presence of N-nitrosodimethylamine (NDMA) close or above the acceptable concentration limit in affected lots.
RecallHealth product recall | 2022-03-11
Presence of particulate matter in affected lots.
RecallHealth product recall | 2022-03-07
Presence of impurity N-Nitroso-quinapril above the acceptable concentration limit in affected lots.
RecallHealth product recall | 2022-03-04
Presence of impurity N-Nitroso-propanolol above the acceptable concentration limit in affected lots.
RecallHealth product recall | 2022-03-02